AAO Preferred Practice Pattern: consensus follow-up intervals

Target IOP achieved	Progression of damage	Duration of control (months)	Follow-up interval, mild-moderate (months)	Follow-up interval, severe (months)
“Yes”	“No”	“≤6”	“3–6”	“3–4”
“Yes”	“No”	“>6”	“6–12”	“3–6”
“Yes”	“Yes”	“NA”	“1–3”	“1–2”
“No”	“Yes”	“NA”	“1–2”	“1–2”
“No”	“No”	“NA”	“1–6”	“1–3”

AAO Preferred Practice Pattern: adherence assessment and education at each visit

“Adherence to medical therapy should be assessed and addressed at each visit (see Medical Management section for more details).” (opens the source at this quote in a new tab)
“Ophthalmologists or trained staff should consider providing instructions to patients, and companions if applicable, on drop administration techniques and having patients demonstrate their preferred technique in the office.” (opens the source at this quote in a new tab)
“Thus, adherence interventions are left to the judgment of the treating ophthalmologist. (I-, Moderate Quality, Discretionary Recommendation)” (opens the source at this quote in a new tab)

European Glaucoma Society guidelines: identifying and improving nonadherence

“Clinicians are unable to detect non-adherence unless such information is volunteered by patients.” (opens the source at this quote in a new tab)
“Adherence may be improved by simplifying the drop regimen, with patient education, by improving communication and setting alarms/messages.” (opens the source at this quote in a new tab)
“– Always evaluate adherence to treatment and monitoring schedule.” (opens the source at this quote in a new tab)

NICE NG81: instillation technique and adherence checks

“Demonstrate correct eye drop installation technique and observe the patient using the technique when eye drops are first prescribed. [2022]” (opens the source at this quote in a new tab)
“Ask about adherence to treatment and check the eye drop instillation technique in people with COAG whose IOP has not been reduced sufficiently to prevent the risk of progression to sight loss, despite pharmacological treatment with a generic PGA. [2009, amended 2022]” (opens the source at this quote in a new tab)

SEE program: personalized glaucoma coaching randomized trial

“Of 236 participants enrolled (108 in UM and 128 in HFHS), 235 (mean [SD] age, 67.3 [10.9] years; 124 [53%] female) were randomized to the SEE intervention (n = 117) or control (n = 118).” (opens the source at this quote in a new tab)
“Medication adherence was significantly better in the SEE intervention group compared with that among control participants (mean [SD], 77.6% [19.7%]; n = 113 vs 58.0% [25.2%]; n = 114; difference, 19.7%; 95% CI, 13.7 to 25.6; P < .001), and more achieved 80% or greater adherence (62 of 113 [54.9%] vs 27 of 114 [23.7%]; P < .001).” (opens the source at this quote in a new tab)

Cochrane review of multifaceted behavioral adherence interventions

“We included 17 RCTs that enrolled 4536 participants, ranging from 64 to 1800 per study.” (opens the source at this quote in a new tab)

Corneal endothelial monitoring for intracameral implants

“Perform specular microscopy to evaluate the corneal endothelium and establish pre-implantation baseline corneal endothelial cell density prior to the initial administration of iDose TR and prior to each readministration” (opens the source at this quote in a new tab)

Perioperative responsibilities after glaucoma surgery

“Perform follow-up evaluations as indicated based on the procedure and specific clinical scenario to evaluate visual acuity, IOP, the status of the anterior segment and posterior segments” (opens the source at this quote in a new tab)

Referral and multidisciplinary support

“If the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with glaucoma can be referred for and encouraged to use appropriate vision rehabilitation, social services, and counseling.” (opens the source at this quote in a new tab)

Care management programs specific to the BIM-IOL System

No evidence found.

Absence of a specular microscopy monitoring requirement for the bimatoprost implant

“Because of the large safety margin with a single implant, there is no regulatory requirement of specular microscopy monitoring in the bimatoprost implant prescribing information. Use of bimatoprost implant with multiple administrations would be off-label at the time of publication, and this is currently not recommended.” (opens the source at this quote in a new tab)